Immuneel key facts
- Developer of a cell therapy intended to provide cell and gene therapies for cancer treatment.
- Immuneel’s last known valuation is $67.9M.
- It has raised $38.0M; the latest was Later Stage VC ($12.0M) in Jul 2024.
- Notable investors include Khosla Ventures, F-Prime Capital, Eight Roads, Ranjan Pai, True North — 16 tracked in total.
- Status: Privately Held (backing).
Who backs Immuneel
16+Membership and data by Private Market View
- ·The complete investor list: 16 names
- ·Watch Immuneel: the Monday email on marks, rounds and moves
Immuneel funding rounds
No funding rounds for Immuneel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Immuneel valuation
Immuneel's last known valuation is $67.9 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Immuneel investors
16 investors are on record for Immuneel, including Khosla Ventures, F-Prime Capital, Eight Roads and Ranjan Pai.
About Immuneel
Developer of a cell therapy intended to provide cell and gene therapies for cancer treatment. The company develops CAR-T cell therapies extracted from patients' blood cells by using genetic engineering that modifies healthy immune cells to target cancerous cells, enabling cancer patients to access transformational cell-based immunotherapies.
- Sector
- Healthcare
- HQ
- Bengaluru, India
- Founded
- 2018
- Employees
- 78
- Website
- immuneel.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Immuneel’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.